|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Clinical Solutions |
|---|---|
| Information provided by: | NIH AIDS Clinical Trials Information Service |
| ClinicalTrials.gov Identifier: | NCT00002167 |
Purpose
To determine the objective tumor response and remission rate of AIDS-related Kaposi's sarcomas (KS) following a single dose of tin ethyl etiopurpurin (SnET2) followed by photodynamic therapy (PDT). To determine the systemic and local toxicity, and morbidity safety profile of SnET2-PDT.
| Condition | Intervention | Phase |
|---|---|---|
|
Sarcoma, Kaposi HIV Infections |
Drug: Tin ethyl etiopurpurin |
Phase II |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Primary Purpose: Treatment |
| Official Title: | Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary. |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients must have:
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Patients with the following prior conditions are excluded:
Excluded within 7 days of therapy:
Excluded within 3 months of therapy:
Excluded within 6 months of therapy:
Prior Medication:
Excluded:
Prior Treatment:
Excluded within 3 months prior to therapy:
Contacts and Locations| United States, California | |
| Cedars Sinai Med Ctr | |
| Los Angeles, California, United States, 90048 | |
| Univ of Southern California / Los Angeles | |
| Los Angeles, California, United States, 90033 | |
| Univ of California / San Francisco / Dermatology | |
| San Francisco, California, United States, 94143 | |
| United States, Colorado | |
| Health One - Rocky Mountain Cancer Ctr | |
| Denver, Colorado, United States, 80218 | |
| United States, New York | |
| Buffalo Gen Hosp / PDT Ctr | |
| Buffalo, New York, United States, 14203 | |
| United States, Tennessee | |
| Thompson Cancer Survival Ctr | |
| Knoxville, Tennessee, United States, 37916 | |
More Information
| ClinicalTrials.gov Identifier: | NCT00002167 History of Changes |
| Other Study ID Numbers: | 261A |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
|
Skin Neoplasms Sarcoma, Kaposi Acquired Immunodeficiency Syndrome |
Photochemotherapy tin etiopurpurin Radiation-Sensitizing Agents |
|
HIV Infections Acquired Immunodeficiency Syndrome Sarcoma, Kaposi AIDS-Related Opportunistic Infections Sarcoma Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Herpesviridae Infections |
DNA Virus Infections Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Neoplasms, Vascular Tissue Opportunistic Infections Infection Parasitic Diseases Radiation-Sensitizing Agents Tin etiopurpurin Physiological Effects of Drugs Pharmacologic Actions Photosensitizing Agents Dermatologic Agents Therapeutic Uses |